Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 157

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 157
---
 audit and non-audit services
to be provided by the independent registered public accounting firm or any other registered public accounting firm engaged by us, and
establishing pre-approval policies and procedures;

●reviewing and discussing with the independent
registered public accounting firm all relationships the auditors have with us in order to evaluate their continued independence;

●setting clear hiring policies for employees or
former employees of the independent registered public accounting firm;

●setting clear policies for audit partner rotation
in compliance with applicable laws and regulations;

●obtaining and reviewing a report, at least annually,
from the independent registered public accounting firm describing (1) the independent registered public accounting firm’s internal
quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review,
of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years
respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;

●meeting to review and discuss our annual audited
financial statements and quarterly financial statements with management and the independent registered public accounting firm, including
reviewing our specific disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”;

●reviewing and approving any related party transaction
required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction;
and

●reviewing with management, the independent registered
public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence
with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial
statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting
Standards Board, the SEC or other regulatory authorities.

Compensation Committee

We have established a compensation committee of
the board of directors. The members of our compensation committee are G. Sridhar Prasad and Myron W. Shulgan. Mr. Shulgan serves as chair
of the compensation committee. We have adopted a compensation committee charter, which details the purpose and responsibility of the compensation
committee, including:

reviewing and approving on an annual basis the
corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating our Chief Executive Officer’s
performance in light of such goals and objectives and determining and approving the remuneration (if any)